The potential effect of age on the natural behavior of bladder cancer: Does urothelial cell carcinoma progress differently in various age groups?  by Gunlusoy, Bulent et al.
Kaohsiung Journal of Medical Sciences (2016) 32, 261e266Available online at www.sciencedirect.com
ScienceDirect
journal homepage: http: / /www.kjms-onl ine.comORIGINAL ARTICLEThe potential effect of age on the natural
behavior of bladder cancer: Does urothelial
cell carcinoma progress differently in various
age groups?
Bulent Gunlusoy, Yasin Ceylan, Tansu Degirmenci, Ozgu Aydogdu,
Ibrahim Halil Bozkurt, Tarik Yonguc, Volkan Sen*, Zafer KozaciogluDepartment of Urology, Bozyaka Training and Research Hospital, Izmir, TurkeyReceived 4 November 2015; accepted 1 March 2016
Available online 10 April 2016KEYWORDS
Age;
Bladder cancer;
Progression;
Recurrence;
Urothelial cell
carcinomaConflicts of interest: All authors d
* Corresponding author. Bozyaka Tra
35340, Turkey.
E-mail address: sen_volkan@yahoo
http://dx.doi.org/10.1016/j.kjms.201
1607-551X/Copyright ª 2016, Kaohsiu
CC BY-NC-ND license (http://creativeAbstract We aimed to evaluate the potential effect of age on the natural behavior of bladder
cancer and to compare these findings between different age groups. The clinical and patho-
logic data of 239 patients treated at our institution between 1994 and 2014 were analyzed.
The patients were classified into three groups according to age:  40 years (Group 1), 41
e59 years (Group 2), and  60 years (Group 3). The following data were collected: character-
istics of the patients, initial pathological findings after transurethral resection, tumor stage
and grade, tumor size and multiplicity, and disease recurrence and progression. The mean
age of the patients at initial diagnosis was 34.2 5.5 years, 53 5.1 years, and 71.1 7 years
in Groups 1, 2, and 3, respectively. There were 207 (86.6%) patients with nonmuscle-invasive
urothelial bladder cancer and 32 (13.4%) patients with muscle-invasive disease. Tumor recur-
rence was significantly lower in Group 1 than in Group 2 (pZ 0.001) and Group 3 (pZ 0.001).
Although the time to tumor recurrence was significantly different between the three groups
(pZ 0.001), no significant difference was noted in the time to progression (pZ 0.349). Pa-
tients with urothelial cancer younger than 40 years tend to have single and small tumors.
The tumor recurrence rate is lower in the younger age group, but tumor progression is similar
in older and younger patients. Therefore, the findings indicate that clinicians should be careful
when assessing the invasiveness of urothelial tumors in younger patients and start treatment as
soon as possible.
Copyright ª 2016, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
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Urothelial cell carcinoma (UCC) is the second most common
urological malignancy in men. UCC is a disease that is
typically found in the elderly; it affects both sexes in the
6th decade or 7th decade of life with a male-to-female ratio
of 7:1 [1e6]. It is rather rare in patients under 40 years, and
< 1% of such tumors present in the 1st decade of life [7,8].
The incidence of UCC in young adults has been increasing in
most parts of the world. Therefore, the pathological fea-
tures of bladder urothelial cancer in young patients and the
clinical management of this disease warrant special
attention [9]. In particular, staging and grading of the
tumor are essential for determining the clinical prognosis of
the cancer.
The impact of age at onset on the tumor biology and
prognosis of patients remains controversial [1]. Because of
the long life expectancy of younger patients, it is important
to use treatment modalities that do not affect their quality
of life. Although the biological behavior and treatment of
bladder cancer are well studied, there are conflicting re-
ports on the clinical behavior and prognosis in patients
younger than 40 years [10e13].
The primary aim of this study is to compare the clinical
behavior, disease recurrence, and progression in patients
younger than 40 years, who have been diagnosed and
treated for urothelial bladder carcinoma, with those of
patients older than 40 years.Methods
Clinical characteristics of the patients, treatment,
and follow-up
This retrospective study was approved by the hospital
ethics committee. We retrospectively analyzed the clinical
and pathologic data of 239 patients with UCC who were first
diagnosed and treated at Bozyaka Training and Research
Hospital, Izmir between 1994 and 2014. The patients were
classified into three groups according to age:  40 years
(Group 1), 41e59 years (Group 2), and  60 years (Group 3).
The patients in Groups 2 and 3 were randomly selected
from patients treated at our department during the study
period. The following data were obtained: the character-
istics of the patients, pathological findings after the initial
transurethral resection, stage and grade of bladder uro-
thelial cancer at the initial transurethral resection of the
bladder tumor (TUR-BT) and/or radical cystectomy; tumor
size and multiplicity; and time to disease recurrence and
progression. The pathologic stage and grade of the bladder
cancer were assessed according to the TNM tumor-stage
classification and the World Health Organization grading
system. Patients with nontransitional cell carcinoma and
those with a history of upper urinary tract involvement
were excluded from the study. Cancer recurrence was
defined as new occurrence of bladder cancer at the same or
different sites of the bladder. Cancer progression was
defined as an increase in the stage or grade of any of the
recurrent tumors. The time to recurrence or progression
was defined as the period between the initial diagnosis andthe recurrence or progression. Death as a result of bladder
cancer or evidence of local or distant disease recurrence
was considered to indicate treatment failure. All patients
with nonmuscle-invasive cancer underwent cystoscopy
(with cytological examination) every 3 months in the first 2
years, every 6 months in the following 2 years, and yearly
thereafter if there were no recurrences. Patients with
muscle-invasive disease underwent radical cystectomy,
radiotherapy, chemotherapy, or a combination of these
therapies.
Statistical analysis
For statistical analyses, patients were stratified into three
groups according to age at presentation. The Chi-square
test, one-way analysis of variance, and KruskaleWallis tests
were used to compare the groups. A p value < 0.05 was
considered to indicate statistical significance. Correlation
analysis was performed by calculating the Spearman cor-
relation coefficient (r). KaplaneMeier analysis of patients
with recurrence or progression was performed by compar-
ison of the groups with the log-rank test.
Results
Clinical characteristics
The clinical characteristics of the patients are presented in
Table 1. The male/female ratio in the three groups was not
significantly different (pZ 0.873). Macroscopic hematuria
was themost common presenting symptom that was found in
a total of 191 patients (78.6%). Pathological examination
performed after TUR-BT revealed that 207 (86.6%) patients
had nonmuscle-invasive urothelial bladder cancer and 32
(13.4%) patients had muscle-invasive urothelial bladder
cancer. Sixty-seven (28%) patients presented with multiple
tumors and 97 (40.5%) patients had tumors> 3 cmat the time
of diagnosis. The number of patients with multiple tumors
was significantly higher in Groups 1 and 3 than in Group 2
(pZ 0.022). The incidence of bladder tumors < 3 cm in
diameter was significantly higher in patients younger than 40
years (pZ 0.012). Although the incidence of nonmuscle-
invasive tumors was higher in Group 1 than in the other
groups, the difference was not statistically significant
(pZ 0.311). According to the distribution of stage and grade,
the incidence of TaG1 tumors was higher in Groups 1 and 3,
and the incidence of T1G3 tumors was significantly lower in
Group 1 (pZ 0.013). Interestingly, there was no significant
difference between the three groups with regard to the
incidence of T2 tumors (pZ 0.254). Table 2 summarizes the
distribution of tumor stage and grade for each group. A pos-
itive correlation was found between age and disease stage
and grade (rZ 0.201, pZ 0.023 for tumor stage; rZ 0.271,
pZ 0.008 for tumor grade).
Tumor recurrence and progression
After TUR-BT, a total of 26 (29.6%) patients with
noninvasive-muscle cancer had postoperative intravesical
Bacillus CalmetteeGue´rin treatment in Group 1. In Group 1,
Table 1 Patients’ characteristics.
Group 1 Group 2 Group 3 p
Patients 91 (38.1) 72 (30.1) 76 (31.8)
Male/female 83/8 64/8 69/7 0.873*
Median follow-up time (mo) 40.3 34.3 39.4
Age (y), mean SD 34.2 5.5 53.0 5.1 71.1 7.5 0.001╫
Multiple tumors 27 (29.7) 12 (16.7) 28 (26.9) 0.022*
Single tumors 64 (70.3) 60 (83.3) 48 (63.1)
Tumor size
< 3 cm 65 (71.5) 38 (52.8) 39 (51.3) 0.012*
> 3 cm 26 (28.5) 34 (47.2) 37(48.7)
Muscle invasive disease 8 (8.6) 11 (15.2) 13 (17.1) 0.311*
Nonmuscle invasive disease 83 (91.4) 61 (84.8) 63 (82.9)
Symptoms
Hematuria 71 (78) 58 (80.5) 62(81.5) 0.838*
Irritative voiding symptoms 12 (13.1) 7 (9.7) 8 (10.5) 0.761*
Urinary infections 6 (6.5) 5 (6.9) 5(6.5) 0.995*
Pelvic pain 2 (2.1) 2 (2.7) 1(1.3) 0.821*
╫One-way analysis of variance; * Chi-square test.
SDZ standard deviation.
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which corresponds to a recurrence rate of 64.7% in the first
2 years after surgery. Of the 17 patients, 10 (58.9%) had one
recurrence, five (29.4%) had two recurrences, and two
(11.7%) had three recurrences. Further, in Group 1, in eight
patients, the tumor progressed to a higher grade (Grade
1e2 in 6 patients, and Grade 2e3 in 2 patients), and in two
patients, the tumor progressed to a higher stage (from Ta to
T1).
Twenty-nine (40.5%) patients in Group 2 and 31 (40.7%)
patients in Group 3 underwent postoperative intravesical
therapy. Further, 34 (47.2%) patients in Group 2 and 29
(38.2%) patients in Group 3 had recurrences during follow-
up within the first 2 years after surgery. Twenty-four
(33.3%) patients and 19 (25%) patients from Groups 2 and
3, respectively, had one recurrence; five (6.9%) patients
and eight (10.5%) patients from Groups 2 and 3, respec-
tively, had two recurrences; and five (6.9%) patients and
two (2.6%) patients from Groups 2 and 3, respectively, had
three recurrences. In Group 2, the tumor progressed to a
higher grade in 12 patients (Grade 1e2 in 8 patients, and
Grade 2e3 in 4 patients), and the tumor progressed to a
higher stage in four patients. In Group 3, the tumorTable 2 Distribution of stage and grade according to
groups.
Stage Group 1 Group 2 Group 3 p
TaG1 35 5 23 0.001
TaG2 4 6 1 0.108
TaG3 2 0 0 NA
T1G1 27 16 13 0.155
T1G2 12 23 14 0.011
T1G3 3 11 12 0.013
T2 7 11 11 0.254
T3 1 0 2 NAprogressed to a higher grade in eight patients (Grade 1e2 in
4 patients, and Grade 2e3 in 4 patients), and the tumor
progressed to a higher stage in four patients.
The overall recurrence rate at 3 years was 18.6%, 47.2%,
and 38.2% in Groups 1, 2, and 3, respectively. Tumor
recurrence was significantly lower in Group 1 than in Group
2 (pZ 0.001) and Group 3 (pZ 0.001). However, no sig-
nificant difference was found between Groups 2 and 3 with
regard to the tumor recurrence rate (pZ 0.596). The tumor
recurrence rate was observed to increase with age, while
the tumor progression rate was similar in all the patients
(pZ 0.15). The time to tumor recurrence was significantly
different between the three groups (pZ 0.001), whereas
no significant difference was noted in the time to pro-
gression (pZ 0.349; Table 3). The KaplaneMeier plot for
patients with recurrence is shown in Figure 1. There was a
significant difference in the median recurrence time be-
tween Groups 1 and 2 and between Groups 1 and 3
(p< 0.001 and pZ 0.005, respectively).
Treatment
Of the 32 (13.3%) patients in whom the tumor had invaded
the muscle, eight were in Group 1, 11 in Group 2, and 13 in
Group 3. Twenty-three (9.6%) patients with muscle-Table 3 Tumor recurrence and progression of the groups.
Group 1 Group 2 Group 3 p
Tumor recurrence 17 34 29 0.001*
Tumor progression 10 16 12 0.15*
Mean tumor recurrence
time (mo)
13.6 8.7 9.2 0.001**
Mean tumor progression
time (mo)
15.7 12.4 10.1 0.349**
*Chi-square test; **KruskaleWallis test.
Figure 1. KaplaneMeier plot for patients with recurrence.
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resistant high-grade superficial transitional cancer un-
derwent radical cystectomy. The diversion method used
was the Studer pouch in six patients and ileal conduit in 17
patients. According to our findings, a greater number of
patients from Groups 2 and 3 than Group 1 underwent
cystectomy [17 (11.4%) vs. 6 (6.5%), p< 0.005]. Of the
patients who presented with initial stage T1 tumors, 12
(9%) underwent cystectomy. In four (12.5%) patients,
cystectomy was performed within 14.6 months after
diagnosis due to refractory high-grade nonmuscle-invasive
disease, and in three patients (10.3%) it was performed
because the tumor progressed to a muscle-invasive form.
The age of the eight patients with muscle-invasive disease
ranged between 26 years and 39 years. Overall, four pa-
tients with muscle-invasive disease at the initial diagnosis
underwent cisplatin-based chemotherapy because of
distant metastasis, and five patients underwent cisplatin-
based adjuvant chemotherapy because of lymph node
metastasis.Discussion
Among the various tumors that occur in the urinary system,
bladder tumors are frequently detected in older patients,
but are rarely found in individuals younger than 40 years
[14]. The occurrence of bladder tumors in younger in-
dividuals can be a major social problem that affects the
patient’s quality of life and concerns both patients and the
their relatives. They are anxious to learn precise knowledge
about prognosis of tumor, which may affect their future
lives. Radical cystectomy for muscle-invasive or high-graderecurrent superficial bladder cancer is suitable for elderly
patients. However, if this procedure is undertaken in young
male patients, surgeons must pay attention to preventing
postoperative infertility and erectile dysfunction. More-
over, it is necessary to perform a nerve-sparing procedure
and orthotopic neobladder urinary diversion to ensure good
quality of life and body image [15]. In this study, we eval-
uated the natural history of bladder cancer in patients aged
40 years or younger by comparing their findings with those
of patients older than 40 years. This comparison provides
important insight into the treatment and prognosis of these
tumors in younger patients.
Gross hematuria, which is the most common presenting
symptom in young adults, should be carefully evaluated by
physicians and the underlying cause should be promptly
investigated. As in elderly patients, hematuria in younger
patients is a serious condition for which differential diag-
nosis is required. The duration from presentation of the
initial symptom to definitive diagnosis can be longer in
younger patients than in older patients as younger patients
are usually too reluctant to undergo cystoscopy. Nomikos
et al. [13] pointed out that delay in diagnosis is common in
younger patients because of low incidence of bladder
cancer and the predominance of benign causes of hema-
turia in this age group; therefore, an aggressive work-up is
usually not performed in younger patients who present with
hematuria. The present study confirmed that hematuria is
the most common clinical symptom in all age groups.
However, irritative symptoms should not be overlooked, as
they are the second most common complaint.
Bladder cancer tends occur more in men than women. In
the present study, the male/female ratio was similar to that
reported in previous studies, with urothelial bladder
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[17] reported that although there is a male dominance, the
percentage of female patients with UCC increases with age;
this is probably related to the changes in estrogen level in
women with age. Likewise, our study showed that the dis-
ease was predominant in men (91.2%). Although it was not
statistically significant, the male-to-female ratio was
slightly lower in older than in younger patients.
The prognosis of the disease is important in younger
patients; as these patients have a longer life expectancy,
the curative treatment undertaken should only have a
minimal effect on the patient’s quality of life. The histo-
pathologic characteristics of tumors are very important
and give us prognostic information about the clinical
behavior of the tumor. In their study on 152 patients
younger than 40 years, Compe´rat et al. [18] found that
histological grade, stage, and multifocality were strongly
predictive of tumor recurrence. Haukaas et al. [19] re-
ported that tumor multicentricity at presentation is a
feature associated with a shorter recurrence-free interval.
Ozbey et al. [16] found that 64% of their younger patients
with UCC had a single bladder tumor. The findings of our
study were similar, as 70.3% of our patients had single
tumors at initial diagnosis. Madrid Garcı´a et al. [20]
observed a 12.5% recurrence rate without any progres-
sion. The recurrence-free survival rate decreases with in-
crease in age [17]. This is probably because bladder cancer
tends to be well differentiated in patients younger than 40
years [17]. In our series, 91 patients (38%) younger than 40
years were initially diagnosed with superficial cancer and
had a 18.6% recurrence rate (mean, 13.6 months). The
disease recurrence rates in Groups 1, 2, and 3 were 18.6%,
47.2%, and 38.2%, respectively. The recurrence rate was
greater in older patients than in younger patients, and the
time to tumor recurrence was significantly longer in pa-
tients younger than 40 years. Patients younger than 40
years had lower tumor stage and grade than patients older
than 40 years. In patients younger than 40 years (Group 1),
most stage Ta and T1 tumors were of Grade 1. The per-
centage of well-differentiated tumors decreased with age.
Moreover, in our study, the number of T1G3 tumors, which
carry a greater risk of progression, was significantly lower
in younger patients. Masuda et al. [14] also reported that
the malignancy grade of bladder tumors in younger pa-
tients is generally not high. They stated that the possibility
of mutation in the undetermined gene regions that are
responsible for tumor malignancy grades is lower in young
patients, because the amount of exposure to bladder
carcinogens is lower in younger patients than in older pa-
tients [14]. In another study, Yossepowitch and Dalbagni
[11] pointed out that the higher incidence of high-grade
tumors in older populations should be carefully inter-
preted, as the classification system for tumors have un-
dergone several modifications over the years and there is a
possibility of interobserver variability in these studies. In
our study, too, patients were included from a relatively
wide time span of 20 years, which could cause disparity in
the interpretation of pathological findings. Our results
revealed that the incidence of T1G2 tumors was lower in
patients younger than 40 years (nZ 12) than in patients
aged  40 years (nZ 37). Similarly, the incidence of T1 G3
tumors was significantly lower in the younger age group.Bladder tumors in younger patients are mainly treated
with bladder preservation therapies. However, the clinical
behavior of high-stage and high-grade disease in younger
patients seems to be similar to that in older patients [13].
This is a very important finding in deciding the treatment
strategy for bladder cancer in younger patients. Although
the incidence of muscle-invasive cancer in this group is
not as high as that in elderly patients, the incidence is
still rather high. There are cases in which total cys-
tectomy was used in patients with unfavorable prognostic
indicators such as tumor diameter > 3 cm, high-grade and
high-stage tumors, and multicentric tumors at initial
diagnosis. In our series, muscle-invasive disease was found
in eight patients (7%) who were younger than 40 years,
and there was no significant difference between the three
groups with regard to the percentage of T2 tumors. This is
probably because the incidence of muscle-invasive dis-
ease was similar between the three age groups as a result
of the delay in initial diagnosis in younger patients. No
significant difference was noted with regard to the pro-
gression rate and time to progression between the three
groups.
The present study has some limitations. Firstly, our
study was retrospective in nature. Further, due to the wide
span of the study period, interobserver variability will need
to be accounted for. Lastly, although the significance of
carcinoma in situ is well known in the case of UCC, this
entity is underreported in the findings of pathological
examinations.
Young patients with urothelial cancer tend to have single
and small tumors. The outcomes of the current study
revealed that although the tumor recurrence rate is lower
in younger patients, tumor progression is similar to that in
older patients. Further, the incidence of muscle-invasive
disease was similar in the different age groups. Therefore,
clinicians should be aware of the possible invasiveness of
bladder cancer in younger patients, and similar manage-
ment strategies should be used in both old and young pa-
tients. In particular, delayed diagnosis as a result of which
conservative management approaches cannot be under-
taken is a major problem in this group of patients.
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